1 October 2025

Bimiralisib, Topical PI3K/mTOR Inhibitor Shows Up To 92% Clearance Rate And Superior Tolerability In Proof-Of-Concept Actinic Keratosis Study

25 July 2025

In the Spotlight: A Personal Side of Our CEO

16 June 2025

Swiss Rockets Featured in Finanz und Wirtschaft: Strong Industry Recognition and Promising Clinical Outlook

7 March 2025

Torqur AG Presents Interim Phase 2 Clinical Trial Results at American Academy of Dermatology

10 September 2024

Andreas Emmenegger new Group Chief Financial Officer (CFO) and Chief Business Officer (CBO)

15 April 2024

Torqur AG Announces First Patient Dosed in Phase 2 Clinical Trial of Bimiralisib in Actinic Keratosis

20 March 2024

Swiss Biotech TORQUR AG Unveils Groundbreaking Data on New Cancer Drug Candidate Bimiralisib

20 September 2023

Swiss Rockets AG and its subsidiary Torqur AG welcome four key scientific members

15 May 2023

Torqur AG's cancer drug candidate bimiralisib with promising new study results

18 April 2023

Swiss Rockets AG Welcomes Three New Key Members To The Team

23 January 2023

Swiss Rockets further strengthens the development of its phase II cancer drug candidate bimiralisib

31 January 2023

Dr. Vladimir Cmiljanovic is a recipient of the 2023 Nikola Tesla Spirit Award